2-amino-9-(2-hydroxyethoxymethyl)-1H-purin-6-one;2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-1H-purin-6-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 2-amino-9-(2-hydroxyethoxymethyl)-1H-purin-6-one;2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-1H-purin-6-one
• 化学式: C18H26N10O6
• 分子量: 478.5
• InChiKey: YACJYBNPFKPGLM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.64
• 重原子数：
  34
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  241
• 氢给体数：
  7
• 氢受体数：
  8

文献信息

• Labyrinthopeptins as anti-viral agents
  申请人：Helmholtz-Zentrum Für Infektionsforschung GMBH

  公开号：US11331371B2

  公开（公告）日：2022-05-17

  The present invention relates to novel labyrinthopeptin derivatives. These labyrinthopeptin derivatives are useful for the treatment of infectious diseases, such as an infectious disease caused by an infection with human respiratory syncytial virus (RSV), Kaposi sarcoma-associated herpesvirus (KSHV), cytomegalovirus (CMV/HCMV), dengue virus (DENV), chikungunya virus (CHIKV), tick-borne encephalitis virus (TBEV; FSME virus), vesicular stomatitis Indiana virus (VSV), zika virus (ZIKV) and/or hepatitis C virus (HCV). Said labyrinthopeptin derivatives are also useful for analyzing the mode of action of labyrinthopeptins. Also encompassed by the present invention are labyrinthopeptins for use in treating an infectious disease, in particular an infectious disease caused by an infection with any one of the viruses selected from RSV, KSHV, CMV, CHIKV, TBEV, VSV, ZIKV and HCV. The invention further relates to a combination of labyrinthopeptin A1 and A2 for use as a medicament, e.g. for treating an infectious disease caused by an infection with RSV, KSHV, CMV, DENV, CHIKV, TBEV, VSV, ZIKV and/or HCV.

  本发明涉及新型迷走神经肽衍生物。这些迷走神经肽衍生物可用于治疗传染性疾病，如感染人类呼吸道合胞病毒（RSV）、卡波西肉瘤相关疱疹病毒（KSHV）、巨细胞病毒（CMV/HCMV）、登革热病毒（DENV）、基孔肯雅病毒（CHIKV）、蜱传脑炎病毒（TBEV；FSME病毒）、水泡性口炎印第安纳病毒（VSV）、寨卡病毒（ZIKV）和/或丙型肝炎病毒（HCV）。上述迷走神经肽衍生物还可用于分析迷走神经肽的作用模式。本发明还包括用于治疗传染病的迷走神经肽，特别是由选自 RSV、KSHV、CMV、CHIKV、TBEV、VSV、ZIKV 和 HCV 的任何一种病毒感染引起的传染病。本发明还涉及一种迷走神经肽 A1 和 A2 的组合物，可用作药物，例如用于治疗由 RSV、KSHV、CMV、DENV、CHIKV、TBEV、VSV、ZIKV 和/或 HCV 感染引起的传染性疾病。
• PRODRUGS ACTIVATED BY RNA-DEPENDENT DNA-POLYMERASES
  申请人：Protera S.R.L.

  公开号：EP1778254A2

  公开（公告）日：2007-05-02
• ANTIVIRAL PATCH
  申请人：Bouty S.p.A.

  公开号：EP2370067B1

  公开（公告）日：2013-11-06
• LABYRINTHOPEPTINS AS ANTI-VIRAL AGENTS
  申请人：Helmholtz-Zentrum für Infektionsforschung GmbH

  公开号：EP3377519B1

  公开（公告）日：2021-06-16
• [EN] PRODRUGS ACTIVATED BY RNA-DEPENDENT DNA-POLYMERASES<br/>[FR] PROMEDICAMENTS ACTIVES PAR DES POLYMERASES D'ADN DEPENDANTES DE L'ARN
  申请人：PROTERA S R L

  公开号：WO2006013203A2

  公开（公告）日：2006-02-09

  Herein described are prodrugs activated by RNA-dependent DNA-polymerases, such as telomerase and retroviral reverse transcriptases, their use for the treatment of haematological tumours and of blood and blood derivatives from patients affected by retroviral infections, and their use for the preparation of pharmaceutical compositions, to be used for the treatment of solid tumours, of precancerous states and of diseases caused by infection with retroviruses.